A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

Abstract Background The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejection fraction (LVEF). In addition, chemotherapy an...

Full description

Bibliographic Details
Main Authors: Quentin Jacquinot, Nathalie Meneveau, Marion Chatot, Franck Bonnetain, Bruno Degano, Malika Bouhaddi, Gilles Dumoulin, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Cancer
Subjects:
Breast cancer
HER2 overexpression
Cardiotoxicity
Exercise
Study protocol
Supportive care
Online Access:http://link.springer.com/article/10.1186/s12885-017-3420-4

Internet

http://link.springer.com/article/10.1186/s12885-017-3420-4

Similar Items